Literature DB >> 8607729

Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated.

S E Vartivarian1, K A Papadakis, E J Anaissie.   

Abstract

BACKGROUND: Stenotrophomonas (Xanthomonas) maltophilia has emerged as a causative agent of serious nosocomial infections. However, well-documented cases of urinary tract infection with this organism have rarely been reported.
METHODS: review of the medical records of patients admitted to a large cancer center with cultures yielding S maltophilia from urinary sources during a 15-month period.
RESULTS: All urinary tract infections were serious: 13 were complicated and two were acute uncomplicated pyelonephritis. The urinary tracts of 13 other patients were colonized with S maltophilia. Most of the colonized and infected patients were hospitalized with genitourinary malignancy, underwent urinary catheterization, and were receiving antibiotics inactive against S maltophilia. Neutropenia and urinary structural abnormalities were significantly associated with infection. The clinical course of infection was usually severe: fever (100%), sepsis disorder (47%), neutrophilia (70% of patients without neutropenia), bacteremia (13%) and death (7%). Still, response to treatment was prompt.
CONCLUSIONS: Stenotrophomonas maltophilia urinary tract infection is usually associated with a severe clinical course. Risk factors for urinary colonization by this organism include hospitalization, urinary catheterization, and administration of inactive antibiotics. Risk factors for urinary tract infection include neutropenia and urinary structural abnormalities. In the presence of these risk factors, treatment of S maltophilia should be considered in patients with urinary colonization by the organism or in those with nosocomial urinary tract infection caused by an unknown pathogen and that is unresponsive to therapy with the antibiotics that are used to treat the common uropathogens.

Entities:  

Mesh:

Year:  1996        PMID: 8607729

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  25 in total

1.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

3.  Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR.

Authors:  P W Whitby; K B Carter; J L Burns; J A Royall; J J LiPuma; T L Stull
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

7.  Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Authors:  Iris H Chen; James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 8.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

9.  Isolation and characterization of novel giant Stenotrophomonas maltophilia phage phiSMA5.

Authors:  Hsiao-Chuan Chang; Chiy-Rong Chen; Juey-Wen Lin; Gwan-Han Shen; Kai-Ming Chang; Yi-Hsiung Tseng; Shu-Fen Weng
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

Review 10.  Community-acquired Stenotrophomonas maltophilia infections: a systematic review.

Authors:  M E Falagas; A C Kastoris; E K Vouloumanou; G Dimopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.